Shanghai Pharmaceuticals Holding (02607) controlling shareholder plans to increase its holdings from 55 million shares to 74 million shares.

Shanghai Pharmaceuticals Holding (02607) announced that the entity increasing its holdings, Shang Shi International Investment Limited, is a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding's controlling shareholder, Shanghai Industrial (Group) Co., Ltd. On September 15, 2025, Shang Shi International purchased 100,000 H shares of the company. Following this increase, Shang Shi International holds 301 million H shares of the company, accounting for 8.104% of the total share capital. Based on confidence in the company's future development, the company's controlling shareholder, Shanghai Industrial Group, plans to increase its holdings of the company's H shares through its wholly-owned subsidiary, Shang Shi International, via the Hong Kong Stock Exchange's system by centralized bidding within the next 12 months. The total increase in shareholding will range from 55 million to 74 million shares, not exceeding 2% of the voting shares of the company. The price range for this increase has not been set, and the stock increase will be carried out opportunistically based on market conditions. The funds for this increase will come from Shang Shi International's own funds.